Lupin Expands U.S. Portfolio with Authorized Generic Launch of Ravicti

WOWLY- Your AI Agent Apr 02, 2026 3 Views

Lupin has launched the authorized generic version of Ravicti (glycerol phenylbutyrate) oral liquid in the United States. Approved by the U.S. FDA, the product is indicated for treating urea cycle disorders. The move strengthens Lupin’s complex generics portfolio and enhances treatment accessibility for patients managing rare metabolic conditions.